Table 3 |
||||||
|
Selected sensitivity analysis |
||||||
|
No. of studies |
No. of patients |
Effect size |
95% CI |
Overall effect (P value) |
Heterogeneity (P value) |
|
|
|
||||||
|
Change in MAP |
(mm Hg) |
|||||
|
All |
12 |
275 |
19 |
(15, 22) |
< 0.001 |
< 0.001 |
|
n > 20 |
5 |
175 |
18 |
(13, 22) |
< 0.001 |
< 0.001 |
|
Pre-PMX MAP < 70 |
3 |
41 |
26 |
(22, 30) |
< 0.001 |
0.85 |
|
Pre-PMX MAP ≥ 70 |
9 |
234 |
16 |
(13, 18) |
< 0.001 |
0.07 |
|
Center duplication |
11 |
268 |
18 |
(15, 21) |
< 0.001 |
< 0.001 |
|
Change in dopamine/dobutamine dose |
(μg/kg per minute) |
|||||
|
Alla |
4 |
96 |
-1.8 |
(-3.3, -0.4) |
0.01 |
< 0.001 |
|
Pre-PMX MAP <70 |
1 |
24 |
-5.0 |
(-6.6, -3.4) |
< 0.001 |
N/A |
|
Pre-PMX MAP ≥ 70 |
3 |
72 |
-0.8 |
(-1.2, -0.4) |
< 0.001 |
0.33 |
|
Change in PaO2/FiO2 ratio |
(Units) |
|||||
|
Alla |
7 |
151 |
32 |
(23, 41) |
< 0.001 |
0.87 |
|
Pre-PMX PaO2/FiO2 ratio < 200 |
2 |
36 |
30 |
(19, 40) |
< 0.001 |
0.62 |
|
Pre-PMX PaO2/FiO2 ratio ≥200 |
5 |
115 |
40 |
(20, 60) |
< 0.001 |
0.84 |
|
Change in endotoxin level |
(pg/ml) |
|||||
|
All |
17 |
455 |
-21.2 |
(-24.9, -17.5) |
< 0.001 |
< 0.001 |
|
Excluding MRSA |
15 |
410 |
-24.1 |
(-28.0, -20.2) |
< 0.001 |
< 0.001 |
|
Pre-PMX endotoxin <30 pg/ml |
5 |
97 |
-9.8 |
(-12.1, -7.5) |
< 0.001 |
0.007 |
|
Pre-PMX endotoxin ≥30 pg/ml |
12 |
358 |
-28.2 |
(-32.3, -24.1) |
< 0.001 |
< 0.001 |
|
Pre-PMX endotoxin <40 pg/ml |
10 |
283 |
-14.9 |
(-18.7, -11.1) |
< 0.001 |
< 0.001 |
|
Pre-PMX endotoxin ≥40 pg/ml |
7 |
172 |
-37.4 |
(-41.9, -32.8) |
< 0.001 |
0.25 |
|
Center duplication |
6 |
225 |
-16.4 |
(-24.0, -8.9) |
< 0.001 |
< 0.001 |
|
Mortality |
Risk ratio |
|||||
|
All |
15 |
920 |
0.53 |
(0.43, 0.65) |
< 0.001 |
0.07 |
|
RCT |
8 |
354 |
0.50 |
(0.37, 0.68) |
< 0.001 |
0.12 |
|
Parallel non-RCT |
7 |
566 |
0.55 |
(0.38, 0.81) |
0.002 |
0.07 |
|
Excluding MRSA |
13 |
840 |
0.55 |
(0.44, 0.69) |
< 0.001 |
0.08 |
|
RCT excluding MRSA |
6 |
274 |
0.55 |
(0.40, 0.76) |
< 0.001 |
0.2 |
|
n > 20 |
7 |
722 |
0.56 |
(0.46, 0.68) |
< 0.001 |
0.17 |
|
APACHE II score < 25 |
9 |
713 |
0.56 |
(0.43, 0.73) |
< 0.001 |
0.06 |
|
APACHE II score ≥ 25 |
6 |
207 |
0.45 |
(0.30, 0.68) |
< 0.001 |
0.25 |
|
28- to 30-day mortality only |
9 |
704 |
0.54 |
(0.43, 0.68) |
< 0.001 |
0.12 |
|
Center duplication |
8 |
673 |
0.61 |
(0.46, 0.82) |
0.001 |
0.03 |
|
|
||||||
|
aFor outcomes of dopamine/dobutamine dose and PaO2/FiO2 ratio, all included studies had a sample size greater than 20. APACHE, Acute Physiology and Chronic Health Evaluation; CI, confidence interval; MAP, mean arterial pressure; MRSA, methicillin-resistant Staphylococcus aureus; N/A, not applicable; PaO2/FiO2, arterial partial pressure of oxygen/fraction of inspired oxygen; PMX, polymyxin B-immobilized fiber column; RCT, randomized controlled trial. |
||||||
|
Cruz et al. Critical Care 2007 11:R47 doi:10.1186/cc5780 |
||||||
